Gruenenthal Gmbh

Grunenthal Gmbh

Katholieke Universiteit Leuven

Gruenethal Gmbh

Gruenthal Gmbh

Melanie Reich

Stefan Schunk

Ruth Jostock

Sabine Hees

Tieno Germann

Stefan Oberboersch

Michael Engels

Michael Haurand

Klaus Schiene

Beatrix Merla

Nils Damann

Marc Rogers

Achim Kless

Florian Jakob

Edward Bijsterveld

Kathy Mackenzie

Jean De Vry

Robert Frank

Sven Kühnert

Henning Steinhagen

Richard Hamlyn

Michael Franz-Martin Engels

René Michael Koenigs

Bernd Sundermann

Werner Guenter Englberger

Gregor Bahrenberg

Thomas Christoph

Hans Schick

Heinz Graubaum

Hagen-Heinrich Hennies

Corinna Sundermann

Matthias Gerlach

Helmut Sonnenschein

Fritz Theil

Christa Kneip

Timo Struenker

Arnaud Marchand

Patrick Chaltin

Utz-Peter Jagusch

Saskia Zemolka

Birgitta Henkel

Amuri Kilonda

Sara Allasia

Thomas Voets

Joris Vriens

Stefan Oberbörsch

Jean-Christophe Vanherck

André Welbers

Kathy Sutton

Ellen Klegraf

Kamila Hennig

Philippe Arzel

Philip Skone

Robert Kirby

Timo Strünker

Brigitta Henkel

The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for the prevention or treatment of said TRPM3 mediated disorders.

Heterocycle derivatives for treating TRPM3 mediated disorders

The invention relates to pyrazolyl substituted tetrahydropyranylsulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Pyrazolyl substituted tetrahydropyranylsulfones

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Heteroaryl substituted heterocyclyl sulfones

Aryl substituted heterocyclyl sulfones

The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Fluoromethyl-substituted pyrrole carboxamides iv

Fluoromethyl-substituted pyrrole carboxamides as CaV2.2 calcium channel blockers

Fluoromethyl-substituted pyrrole carboxamides

The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments.

Substituted spiro compounds and their use for producing pain-relief medicaments

Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

Bradykinin 1 receptor modulating compounds

Substituted sulfonamide compounds with bradykinin receptor (B1R) modulating activity; processes for the preparation thereof, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or inhibit pain and/or other disorders and/or disease states.

Substituted sulfonamide compounds

Substituted sulfonamide compounds corresponding to the formula I processes for the preparation thereof, pharmaceutical compositions containing these compounds and the use of substituted sulfonamide compounds for the preparation of pharmaceutical compositions for treating pain and other conditions at least partly mediated via the bradykinin 1 receptor.

Substituted indole compounds corresponding to the formula I: In which R, R, R, R, R, R, R, A, D, T, q, s and t have defined meanings, processes for the preparation thereof, pharmaceutical compositions containing such compounds and the use of substituted indole compounds for the treatment or inhibition of pain and other conditions which are at least partly mediated by Bradykinin 1 receptors (B1R).

Substituted indole compounds

Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

Substituted spiro-amide compounds

Growing community of inventors

Aachen, Germany

Melanie Reich